-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Bristol-Myers Squibb and Nektar Therapeutics announced that they have decided to close the pre-planned analysis of two late-stage clinical studies of bempegaldesleukin in combination with Opdivo (nivolumab) in renal cell carcinoma and bladder cancer.
bempegaldesleukin and Opdivo global clinical development program
.
At the same time, all other ongoing clinical trials in the therapy's known research and collaborative programs will cease
.
According to public information, Bristol-Myers Squibb reached a clinical cooperation with Nektar in September 2016.
The two parties jointly developed Opdivo and bempeg for the treatment of various types of cancer
.
It is understood that bempeg is an immunostimulatory therapy, and Opdivo is a PD-1 checkpoint inhibitor, and the combination of the two has the potential to produce synergistic effects
.
Bristol-Myers Squibb paid $1 billion upfront to buy $850 million worth of Netkar shares at $102.
60 per share, with a promise that it could continue to pay up to $1.
8 billion in future milestones
.
However, despite the announcement of the termination of the cooperation, the two sides said they would further review the data from the two studies and plan to share the relevant trial results externally
.
Industry analysts believe that although the BMS/Nektar combination therapy cooperation is terminated, on the whole, pharmaceutical companies in the pharmaceutical industry are still very frequent in cooperation on new therapies
.
In recent years, many pharmaceutical companies have announced that they will cooperate with other companies to develop combination therapies and even new drugs
.
Among them, many companies have been making frequent moves in the near future, such as Aide Bio
.
On April 18, 2022, Aide Bio announced that the company signed two cooperation agreements with AstraZeneca
.
First, the company will work with AstraZeneca to promote the company's self-developed companion diagnostic products for the registration of companion diagnostics for prostate cancer patients with homologous recombination repair (HRR) gene mutations in China, the European Union and Japan; second, the company will cooperate with AstraZeneca is jointly advancing the registration of another companion diagnostic product developed by AstraZeneca for the identification of breast cancer patients with BRCA mutations in the European region
.
On April 7, Aide Bio announced that the company recently signed a cooperation agreement with Chi-Med
.
The company will work with Chi-Med to promote the registration of the companion diagnostic reagents independently developed by the company in the Chinese market in the treatment of non-small cell lung cancer with the combination therapy of savatinib and osimertinib mesylate tablets
.
According to reports, this time Chi-Med selected the company as its clinical companion diagnostic partner in China, which is conducive to further enhancing the company's competitiveness in the tumor precision medicine market
.
Since the beginning of this year, in addition to the above-mentioned companies, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico, Bio-Science, BeiGene, etc.
have also successively announced new and diversified cooperation announcements
.
Analysts believe that this is mainly due to changes in the pharmaceutical industry
.
In order to respond to more and more market challenges, it has become a general trend in the industry to accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness
.
In the future, domestic pharmaceutical companies and domestic and foreign pharmaceutical companies will accelerate cooperation to achieve complementary advantages, better promote research and development, accelerate the process of product commercialization, and benefit more patients
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
bempegaldesleukin and Opdivo global clinical development program
.
At the same time, all other ongoing clinical trials in the therapy's known research and collaborative programs will cease
.
According to public information, Bristol-Myers Squibb reached a clinical cooperation with Nektar in September 2016.
The two parties jointly developed Opdivo and bempeg for the treatment of various types of cancer
.
It is understood that bempeg is an immunostimulatory therapy, and Opdivo is a PD-1 checkpoint inhibitor, and the combination of the two has the potential to produce synergistic effects
.
Bristol-Myers Squibb paid $1 billion upfront to buy $850 million worth of Netkar shares at $102.
60 per share, with a promise that it could continue to pay up to $1.
8 billion in future milestones
.
However, despite the announcement of the termination of the cooperation, the two sides said they would further review the data from the two studies and plan to share the relevant trial results externally
.
Industry analysts believe that although the BMS/Nektar combination therapy cooperation is terminated, on the whole, pharmaceutical companies in the pharmaceutical industry are still very frequent in cooperation on new therapies
.
In recent years, many pharmaceutical companies have announced that they will cooperate with other companies to develop combination therapies and even new drugs
.
Among them, many companies have been making frequent moves in the near future, such as Aide Bio
.
On April 18, 2022, Aide Bio announced that the company signed two cooperation agreements with AstraZeneca
.
First, the company will work with AstraZeneca to promote the company's self-developed companion diagnostic products for the registration of companion diagnostics for prostate cancer patients with homologous recombination repair (HRR) gene mutations in China, the European Union and Japan; second, the company will cooperate with AstraZeneca is jointly advancing the registration of another companion diagnostic product developed by AstraZeneca for the identification of breast cancer patients with BRCA mutations in the European region
.
On April 7, Aide Bio announced that the company recently signed a cooperation agreement with Chi-Med
.
The company will work with Chi-Med to promote the registration of the companion diagnostic reagents independently developed by the company in the Chinese market in the treatment of non-small cell lung cancer with the combination therapy of savatinib and osimertinib mesylate tablets
.
According to reports, this time Chi-Med selected the company as its clinical companion diagnostic partner in China, which is conducive to further enhancing the company's competitiveness in the tumor precision medicine market
.
Since the beginning of this year, in addition to the above-mentioned companies, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico, Bio-Science, BeiGene, etc.
have also successively announced new and diversified cooperation announcements
.
Analysts believe that this is mainly due to changes in the pharmaceutical industry
.
In order to respond to more and more market challenges, it has become a general trend in the industry to accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness
.
In the future, domestic pharmaceutical companies and domestic and foreign pharmaceutical companies will accelerate cooperation to achieve complementary advantages, better promote research and development, accelerate the process of product commercialization, and benefit more patients
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
